US Stock Insider Trading | Whitehawk Disclosed 3 Insider Transactions on March 10

K-LinePoet · 2026-03-23T23:33:36+00:00

On March 10, 2026, Whitehawk disclosed an insider transaction in which director Lennon David James sold 5,100 shares on March 2. The company focuses on developing precision therapies targeting genetically defined cancers.

K-LinePoet

2026-03-23 23:33:36

Abstract generation in progress

On March 10, 2026, Whitehawk (WHWK) disclosed three insider transactions. Director Lennon David James sold 5,100 shares on March 2, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 10, 2026	Director	Lennon David James	March 2, 2026	Sell	5,100	3.31	$16,900
March 10, 2026	Executive	BALL BRYAN	March 2, 2026	Sell	1,834	3.31	$6,069.81
March 10, 2026	Executive	Giacobello Scott M.	March 2, 2026	Sell	2,594	3.31	$8,585.10
March 5, 2025	Director	Dalal Anupam	March 4, 2025	Buy	1.56 million	2.40	$3.7464 million
March 4, 2025	Executive	BALL BRYAN	March 3, 2025	Sell	2,147	2.35	$5,045.45
March 4, 2025	Director	Castelein Caley, Zhao Baiteng	March 4, 2025	Buy	2.916 million	2.40	$6.9984 million
March 4, 2025	Executive	BALL BRYAN	March 4, 2025	Buy	100,000	2.40	$240,000
March 3, 2025	Director	Lennon David James	March 3, 2025	Sell	5,690	2.35	$13,400
March 3, 2025	Executive	Giacobello Scott M.	March 3, 2025	Sell	2,806	2.35	$6,594.10
October 3, 2024	Director	Lennon David James	October 3, 2024	Sell	9,689	1.94	$18,800

[Company Information]

Whitehawk Therapeutics, Inc. was incorporated in Delaware on November 16, 2007. The company is a clinical-stage biopharmaceutical company developing precision therapies for genetically defined cancers. Its primary focus is on delivering transformative treatments for cancers driven by mTOR pathway alterations, such as changes in TSC1 or TSC2 genes, where mTOR inhibitors have not been effectively utilized due to pharmacological, delivery, safety, or efficacy issues. Aadi’s main product is FYARRO™, an mTOR inhibitor that binds to human proteins, showing higher tumor accumulation, greater mTOR target inhibition, and enhanced tumor growth suppression.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.